Attorney Docket No.:

MCP-0141

Inventors:

Halpern and England

Serial No.:

09/744,406

Filing Date:

January 22, 2001

Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1-39 (canceled) -

Claim 40: (currently amended) A non-tumorigenic cellular immunogen which promotes tumor regression in a host, said non-tumorigenic cellular immunogen comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming cognate transgene derived by deletion of having a deletion mutation in a sequence of the transgene essential required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wildtype sequence outside the deleted sequence deletion mutation, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of and the target proto-oncogene is selected from the group consisting of AKT-2, c-erbB-2 (HER2/neu), MDM-2, c-myc, cmyb, c-ras, c-src and c-yes.

Attorney Docket No.: MCP-0141

Inventors:

Halpern and England

Serial No.:

09/744,406

Filing Date:

January 22, 2001

Page 4

Claim 41: (currently amended) A method for preparing a non-tumorigenic cellular immunogen which promotes tumor regression in a host, the method comprising:

transfecting cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to the target protooncogene, said non-transforming cognate transgene derived by deletion of having a deletion mutation in a sequence of the transgene essential required for transformation, said deletion mutation rendering the transgene totally nontransforming, and consisting of wild-type sequence outside the deleted sequence deletion mutation, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of AKT-2, c-erb8-2 (HER2/neu), MDM-2, c-myc, c-myb, c-ras, c-src and c-yes.

Claim 42: (currently amended) A non-tumorigenic cellular immunogen which promotes tumor regression in a host, said non-tumorigenic cellular immunogen comprising cells which are allogeneic with respect to the host, said allogeneic cells having been transfected with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming

Attorney Docket No.:

MCP-0141

Inventors:

Halpern and England

Serial No.:

09/744,406

Filing Date:

January 22, 2001

Page 5

mutation in a sequence of the transgene essential required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the deleted sequence deletion mutation, and a strong promoter to drive the expression of the cognate transgene in the transfected cells, wherein the target proto-oncogene is selected from the group consisting of c-erbB-2 (HER2/neu), c-myc and c-src.

Claim 43: (currently amended) A method for preparing a non-tumorigenic cellular immunogen which promotes tumor regression in a host, the method comprising:

transfecting cells which are allogeneic with respect to the host with at least one vector comprising at least one non-transforming transgene cognate to a target proto-oncogene, said non-transforming cognate transgene derived by deletion of having an deletion mutation in a sequence of the transgene essential required for transformation, said deletion mutation rendering the transgene totally non-transforming, and consisting of wild-type sequence outside the deleted sequence deletion mutation, and a strong promoter to drive the expression of the non-transforming cognate transgene in the transfected cells, wherein the

Attorney Docket No.:

MCP-0141

Inventors:

Halpern and England

Serial No.:

09/744,406

Filing Date:

January 22, 2001

Page 6

target proto-oncogene is selected from the group consisting of c-erbB-2 (HER2/neu), c-myc and c-src.